In younger women with breast cancer, a higher incidence of growth-factor receptors, namely HER2, was observed both in terms of protein expression, associated with a more-aggressive phenotype [51,52], and of HER2 gene expression with no predictive value for DFS [50]. This evidence concerns the gene ERBB2 and breast carcinoma.